| Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics CG Santos-Gallego, JA Requena-Ibanez, R San Antonio, K Ishikawa, ... Journal of the American College of Cardiology 73 (15), 1931-1944, 2019 | 528 | 2019 |
| Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction CG Santos-Gallego, AP Vargas-Delgado, JA Requena-Ibanez, ... Journal of the American College of Cardiology 77 (3), 243-255, 2021 | 364 | 2021 |
| Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study JA Requena-Ibáñez, CG Santos-Gallego, A Rodriguez-Cordero, ... Heart Failure 9 (8), 578-589, 2021 | 167 | 2021 |
| Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study CG Santos-Gallego, JA Requena-Ibanez, R San Antonio, ... Cardiovascular Imaging 14 (2), 393-407, 2021 | 144 | 2021 |
| Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility CG Santos-Gallego, JAR Ibanez, RS Antonio, K Ishikawa, S Watanabe, ... Journal of the American College of Cardiology 71 (11S), A674-A674, 2018 | 39 | 2018 |
| Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction CG Santos-Gallego, JA Requena-Ibáñez, B Picatoste, B Fardman, ... Circulation: Cardiovascular Imaging 16 (4), e015298, 2023 | 36 | 2023 |
| Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial JA Requena-Ibáñez, CG Santos-Gallego, A Rodriguez-Cordero, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16 (2), 102417, 2022 | 32 | 2022 |
| EMPA-TROPISM (ATRU-4) Investigators CG Santos-Gallego, AP Vargas-Delgado, JA Requena-Ibanez, ... Randomized trial of empagliflozin in nondiabetic patients with heart failure …, 2021 | 25 | 2021 |
| Prolyl hydroxylase inhibitors: a new opportunity in renal and myocardial protection JA Requena-Ibáñez, CG Santos-Gallego, A Rodriguez-Cordero, MU Zafar, ... Cardiovascular Drugs and Therapy 36 (6), 1187-1196, 2022 | 18 | 2022 |
| SGLT2-inhibitors on HFpEF patients. Role of ejection fraction JA Requena-Ibanez, CG Santos-Gallego, MU Zafar, JJ Badimon Cardiovascular Drugs and Therapy 37 (5), 989-996, 2023 | 11 | 2023 |
| Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy A Garcia-Ropero, CG Santos-Gallego, AP Vargas-Delgado, ... Expert Review of Cardiovascular Therapy 18 (9), 635-642, 2020 | 11 | 2020 |
| Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure CE Angermann, CG Santos-Gallego, JA Requena-Ibanez, S Sehner, ... Nature Cardiovascular Research 2 (11), 1032-1043, 2023 | 10 | 2023 |
| Rationale and design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF patients without Diabetes MS Pérez, J Rodríguez-Capitán, JA Requena-Ibáñez, CG Santos-Gallego, ... Cardiovascular Drugs and Therapy, 1-10, 2023 | 8 | 2023 |
| Not only how much, but also how to, when measuring epicardial adipose tissue JA Requena-Ibáñez, CG Santos-Gallego, AJR Cordero, B Fardman, ... Magnetic Resonance Imaging 86, 149-151, 2022 | 8 | 2022 |
| The SGLT2 inhibitor empagliflozin does not exhibit pro thrombotic effects CG Santos-Gallego, M Zafar, RS Antonio, JAR Ibanez, MBP Botija, ... Journal of the American College of Cardiology 71 (11S), A1852-A1852, 2018 | 8 | 2018 |
| SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction? JA Requena-Ibáñez, CG Santos-Gallego, JJ Badimón Revista Española de Cardiología (English Edition) 75 (10), 833-841, 2022 | 5 | 2022 |
| Effects of empagliflozin on iron metabolism in non-diabetic patients with heart failure. Substudy of the EMPATROPISM randomized trial CE Angermann, CG Santos-Gallego, JA Requena-Ibanez, S Sehner, ... Circulation 144 (25), E584-E584, 2021 | 5 | 2021 |
| Infusion of the ketone body β-hydroxybutyrate improves left ventricular systolic function in an animal model of heart failure with reduced ejection fraction CG SantosGallego, JA Requena-Ibanez, R San Antonio, K Ishikawa, ... Circulation 138 (Suppl_1), A17367-A17367, 2018 | 5 | 2018 |
| Pretreatment with SGLT2 inhibitors ameliorates contrast-induced nephropathy CG Santos-Gallego, G Palamara, JA Requena-Ibanez, AP Vargas, ... Journal of the American College of Cardiology 75 (11_Supplement_1), 1405-1405, 2020 | 4 | 2020 |
| The Sglt2 inhibitor empagliflozin causes a greater reduction in skin sodium content and interstitial volume than loop diuretics in heart failure CG Santos-Gallego, JAR Ibanez, RS Antonio, MBP Botija, K Ishikawa, ... Journal of the American College of Cardiology 75 (11_Supplement_1), 1075-1075, 2020 | 4 | 2020 |
